** Shares of California-based drugmaker Arcutis Biotherapeutics ARQT.O rise 8.2% to $13.20
** Company posted Q4 revenue of $71.36 million late on Tuesday on strong sales of skin disease drug Zoryve, beating analysts' estimate of $60.16 million, according to data compiled by LSEG
** Co also posted quarterly loss of 9 cents per share, narrower than analysts' estimate of 26 cents per share
** Separately, co says the FDA has accepted its marketing application to review Zoryve cream 0.05% to treat mild to moderate atopic dermatitis (AD) in children two to five years old
** Expects to receive regulatory decision by October 12, 2025
** AD, or eczema, is a chronic disease that causes inflammation, redness and irritation of skin
** Zoryve is already approved in the U.S. to treat skin conditions seborrheic dermatitis and plaque psoriasis
** ARQT has risen ~26% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.